Comparative Pharmacology
Head-to-head clinical analysis: AQUATENSEN versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUATENSEN versus ZIAC.
AQUATENSEN vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQUATENSEN (methylclothiazide) is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and blood pressure.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
1-2 mg orally once daily, titrated to blood pressure response; maximum dose 4 mg/day.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours (mean 10 h); clinically, allows twice-daily dosing
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Renal: 50% unchanged; Fecal: 20% (via bile); remainder as inactive metabolites
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Diuretic
Beta Blocker + Diuretic